NexImmune, Inc. products

The injectable modality (AIM INJ) is an injectable pharmaceutical product of AIM nanoparticles decorated with antigen-specific peptides and co-stimulatory molecules appropriate for the disease being targeted. Based on specific size and bio-distribution characteristics, the AIM™ nanoparticles have the ability to engage antigen-specific T cell populations at multiple sites in the body (lymph node, lymphatic system, peripheral blood, spleen, tumor).

NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a precise immune response against disease. An AIM™ Adoptive Cellular Therapy (ACT) product is manufactured using an AIM™ nanoparticle cocktail that contains multiple tumor-specific antigens and the AIM™ Enrichment and Expansion system. Combined, this propriety approach delivers populations of high quality CD8+ antigen-specific T cells within 14 days — optimized for deep and durable response potential.